

STATE OF ALASKA
DEPARTMENT OF COMMUNITY AND ECONOMIC DEVELOPMENT
DIVISION OF BANKING, SECURITIES, AND CORPORATIONS
P.O. BOX 110807
JUNEAU, ALASKA 99811-0807

In the Matter of)
J. P. Morgan Securities Inc.,) Alaska Order 04-03 S
Respondent.)
270 Park Avenue)
New York, NY 10017)
CONSENT ORDER

WHEREAS, J. P. Morgan Securities Inc. ("JPMSI") is a broker-dealer registered in the State of Alaska; and

WHEREAS, coordinated investigations into J. P. Morgan Securities Inc.'s activities in connection with certain of its equity research practices during the period of approximately July 1999 through June 2001 have been conducted by a multi-state task force and a joint task force of the U.S. Securities and Exchange Commission, the New York Stock Exchange ("NYSE"), and the NASD, Inc. ("NASD") (collectively, the "regulators"); and

WHEREAS, J. P. Morgan Securities Inc. has cooperated with regulators conducting the investigations by responding to inquiries, providing documentary evidence and other materials, and providing regulators with access to facts relating to the investigations; and

WHEREAS, J. P. Morgan Securities Inc. has advised regulators of its agreement to resolve the investigations relating to its research practices; and

WHEREAS, J. P. Morgan Securities Inc. agrees to implement certain changes with respect to its research practices, and to make certain payments; and

WHEREAS, J. P. Morgan Securities Inc. elects to permanently waive any right to a hearing and appeal under the Alaska Securities Act (the "Act") with respect to this Administrative Consent Order (the "Order");

NOW, THEREFORE, the Alaska division of banking, securities, and corporations (the "Division"), as administrator of the Act, hereby enters this Order:

FINDINGS OF FACT

A. Background

1. This action concerns the period of July 1, 1999 to June 30, 2001 (the "relevant period"). During that time, several JPMSI predecessor entities engaged in both research and investment banking ("IB") activities.

- 1 1. Research analysts were responsible for providing analyses of the financial outlook
2 of particular companies in the context of the business sectors in which those
3 companies operated and the securities market as a whole.
- 4 2. Research analysts evaluated companies by, among other things, examining
5 financial and other information contained in public filings; questioning company
6 management; investigating customer and supplier relationships; evaluating
7 companies' business plans and the products or services offered; building financial
8 models; and analyzing competitive trends.
- 9 3. After synthesizing and analyzing this information, research analysts drafted
10 research reports and more abbreviated "notes" that typically contained a
11 recommendation, a price target, and a summary and analysis of the factors upon
12 which the analyst relied in issuing the price target and recommendation.
- 13 4. The Firm published research on publicly traded companies, and this research was
14 distributed to the Firm's institutional and private equity customers. Published
15 research was made available through mailing lists, the Firm's website, and
16 subscription services provided by First Call. In addition, the research was made
17 available to some retail customers of another broker dealer and offered via
18 websites offering brokerage and investment services.
- 19 5. In addition to performing these research functions, certain research analysts
20 participated in IB activities.
- 21 6. These IB activities included identifying and/or vetting companies as prospects for
22 IB services, participating in pitches of IB services to companies, participating in
23 "roadshows" associated with underwriting transactions, and speaking to investors
24 to generate interest in underwriting transactions.¹
- 25 7. These IB activities also included participating in commitment committee and due
 diligence activities in connection with underwriting transactions and assisting the
 IB Department in providing merger and acquisition ("M&A") and other advisory
 services to companies.²
8. The Firm encouraged all research analysts to support its businesses, including the
 Firm's IB business, and in some cases, research analysts were expected to
 participate in the foregoing IB activities. The level of analyst participation in these
 IB activities was sometimes significant.
9. For example, in an e-mail dated May 23, 2000, and sent by a research analyst to
 the Head of Research at RESPONDENT JPMSI, the analyst requested approval
 to hire another junior analyst. The analyst stated: "I'd like to get yet another

¹ A "roadshow" is a series of presentations made to potential investors in conjunction with the marketing of an upcoming underwriting.

² The "commitment committee" was responsible for, among other things, evaluating and then either approving or rejecting the Firm's participation in initial public offerings ("IPOs") and other IB transactions.

1 **junior....**The deals are really dragging me down, and I'm not spending nearly
2 enough time with buy-side clients. Even though the market is crap, we continue to
3 process deals in hopes of market recovery....I am trying to remove myself from the
4 day-to-day production of research. I actually like doing it, but it's not what you pay
5 me for." (Emphasis in the original.)

- 6
- 7 10. IB business was an important source of revenue for the Firm. In 2000, the
8 combined operating revenues for JPM and Chase totaled \$32.793 billion, and the
9 combined revenues for the Equity Capital Markets ("ECM") and the M&A
10 Departments at JPM and Chase totaled \$1.687 billion.

11

12 **D. Participation in Investment Banking Activities Was a Factor in Evaluating and**
13 **Compensating Research Analysts**

- 14
- 15 1. The compensation system at the Firm provided an incentive for research analysts
16 to participate in IB activities and to assist in generating IB business for the Firm.
- 17 2. The performance of research analysts was evaluated by the Head of Research
18 through an annual review process and, where not set by contract in advance, the
19 research analyst's bonus was determined through this process.
- 20 3. The Head of Research evaluated the research analysts' job performance through
21 responses to self-evaluation forms; surveys of the sales force; input from the IB,
22 Sales, and Trading departments; consideration of market factors and rankings by
23 investor publications; and, in some cases, written "team reviews" submitted by
24 individual investment bankers.
- 25 4. The self-evaluation forms contained questions on areas constituting the major
 allocations of research analysts' time, including questions relating to participation
 in IB activities.
5. In response to questions relating to participation in IB activities, research analysts
 reported one or more of the following: their IB activities, accomplishments, and
 goals; their participation in lead- and co-managed underwritings; and the fees
 associated with IB transactions on which the analyst worked.
6. For example, the "Investment Banking Activities" section of a 1999 self-evaluation
 form queried: "In what way have you assisted in discovering or executing banking
 transactions (i.e., due diligence sessions, pitches)? Be specific." In response, a
 research analyst stated: "Helped put together and develop pitch books for KV
 Pharma and King Pharmaceuticals;" "Helping to come up with creative ideas and
 contributing to brainstorming sessions with bankers – ad hoc and in biweekly
 Monday meetings;" "Have a good handle on which companies will need financing
 in the near future and stepping up research efforts to ensure a place for H&Q on
 the cover;" and "Increasing responsibility in the office allows [another research
 analyst] to travel and be more active in pitching and winning deals with new
 companies."

- 1 7. In another example, a research analyst stated the following in response to IB
2 questions contained in his year 2000 self-evaluation form: "Completed 21
3 investment banking deals, including 11 lead-managed deals....Biotechnology new
4 issues have generated \$70 million in primary fees in fiscal year 2000 YTD. In
5 2000 we were ranked #1 in healthcare common equity offerings by U.S. Issuers,
6 raising \$3.9 billion and capturing 21.9% market share." In addition, the analyst
7 listed all deals on which he worked that were "Lead Managed," "Co-managed,"
8 "Pitched," and "Pending."
- 9 8. The self-evaluation forms conveyed to research analysts some of the criteria used
10 to evaluate their performance. As reflected in the IB questions contained in the
11 forms, contribution to the Firm's IB business was an important part of the analyst's
12 job.
- 13 9. In some circumstances, research analysts requested that individual investment
14 bankers complete a written "team review" of the analyst, which was then submitted
15 to the Head of Research. In these reviews, the investment banker described his
16 or her contact with the analyst and the analyst's participation in IB activities,
17 including pitch and underwriting activities.
- 18 10. For example, in a 1999 review of a research analyst by an investment banker, the
19 banker stated the following: "I have worked extensively with [this research analyst]
20 over the past year. I probably speak to her everyday [sic] on topics ranging from
21 executing live transactions, evaluating potential business opportunities, drafting
22 'pitch' presentations, coordinating scheduling and marketing efforts across IB, and
23 strategizing about the Internet practice....I consider [her] to be a partner in our
24 building of the firm's Internet franchise and, as a result, probably work more
25 closely with her than anyone in IB."
- 16 11. Research analysts sometimes provided reviews of investment bankers in
17 conjunction with the banker's performance review. In these reviews, analysts
18 described their contact with the banker and referenced participation in specific IB
19 activities.
- 20 12. For example, in an e-mail dated Dec. 14, 2000, a research analyst provided a
21 review of an investment banker. The analyst stated: "I've probably had more
22 opportunity to work with [this investment banker] and observe him in action than
23 anybody else in the bank....[The banker and I] have been in sync about where the
24 quality banking prospects are so that I don't have to fend off garbage banking
25 deals.... • **Built semiconductor banking practice from nothing:**....[The banker
and I] have built a profitable semiconductor banking practice, starting from literally
zero four years ago....In 1999, we posted a couple of successes....With a touch
more luck, we could have doubled the revenue potential this year....We are still
banking the semiconductor sector pretty much the way we did three years ago,
which means going after a dozen or so key prospects (split evenly between
existing public companies and quality IPO candidates) and then doing everything
else opportunistically rather than strategically....The message here is that we have
not developed the semiconductor banking machine that our strongest dozen

1 competitors have, and that makes it hard to gain market share." (Emphasis in the
2 original.)

3 13. Based upon comments in the self-evaluations completed by research analysts and
4 the reviews completed by both analysts and investment bankers, the two groups
5 worked closely on IB transactions and shared a common goal of building the
6 Firm's IB business.

7 14. The Head of Research reviewed the self-evaluations and team reviews and
8 provided a verbal and/or written evaluation of the research analyst. The written
9 evaluations provided feedback on the analyst's performance during the year and in
10 certain cases highlighted the analyst's participation in IB activities, including the
11 revenues generated by IB transactions on which the analyst worked.

12 15. For example, the Head of Research at RESPONDENT JPMSI stated the following
13 in the first paragraph of his year 2000 evaluation of a research analyst: "By every
14 measure, [the research analyst] had an outstanding year in 2000. Most
15 importantly, [he] led the charge in establishing J.P. Morgan as the #1 biotech shop
16 with a resounding 21.9% share of the underwriting wallet in his sector. [He]
17 supported 21 transactions this year, 11 of which were as the lead underwriter.
18 The revenue attributable to these transactions is over \$70 mm." Later in the
19 evaluation, the Head of Research stated that the analyst's contribution to the
20 Firm's "corporate underwriting business" was "enormous."

21 16. Comments by the Head of Research conveyed to research analysts the
22 performance areas that were important to research management and the Firm.
23 Based upon these comments, certain analysts were encouraged to participate in
24 IB activities, increase IB revenues, and enhance the reputation of the Firm's IB
25 franchise.

17. Research analyst bonuses were determined by the Head of Research in his
discretion after considering several factors that contributed to the analyst's market
value.

18. The research analyst's contribution to and impact on the Firm's IB business, and
the fees generated by IB transactions on which the analyst worked, were some of
the factors used to determine the analyst's bonus. If the analyst did not disclose in
the self- evaluation form the fees generated by the IB transactions on which he or
she worked, the Head of Research requested this information from the ECM
Department at the Firm.

E. Investment Banking Interests Influenced the Firm's Decision to Initiate and Maintain Research Coverage

1. In general, the Firm determined whether to initiate and maintain research
coverage based upon institutional investors' interest in the company and/or based
upon IB considerations, such as attracting companies to generate IB business or
maintaining a positive relationship with existing IB clients.

- 1 2. Regarding companies for which the Firm lead- or co-managed an underwriting
2 transaction, research coverage was typically initiated and maintained for a period
of time beyond the transaction.
- 3 3. The Head of Research was responsible for approval of the determination to issue,
4 maintain, and drop research coverage. The Head of Research solicited input from
5 other departments, including the IB Department, to determine the coverage
preferences of those departments. IB considerations sometimes played a role in
the decision to initiate and maintain research coverage.
- 6 4. For example, after the merger of JPM and Chase, the Director of U.S. Equity
7 Research at RESPONDENT JPMSI sent an e-mail entitled: "U.S. Equity
8 Research Organizational Announcement." Attached was an internal memorandum
9 "outlining Investment Banking Coordination Responsibilities," which stated: "One
of the important duties of the Director of Research is to work closely with
Investment Banking to ensure that research resources are appropriately aligned
with identified investment banking opportunities."
- 10 5. In addition, the Head of Research requested that research analysts obtain from
11 investment bankers lists of companies that the bankers wanted under coverage.
- 12 6. For example, an e-mail dated November 4, 1999, from the Head of Research to all
13 equity research analysts, stated: "[T]alk to your counterparts in IB and prepare a
list of the companies that they would like you to cover....Please be sure to have a
conversation with the appropriate bankers before you submit your list."
- 14 7. Some research analysts and investment bankers actively coordinated the initiation
15 and maintenance of research coverage based upon, among other things, IB
16 considerations. This coordination consisted of meetings and communications by
telephone and e-mail.
- 17 8. For example, a research analyst sent an e-mail, dated March 9, 2001, to the
18 Director of U.S. Equity Research at RESPONDENT JPMSI which stated:
19 "[Another research analyst] and I have prioritized the coverage area in
20 coordination with banking, and we are moving to a more **targeted** (no pun
21 intended) investor marketing plan which leverages our combined coverage....We
22 are clearly focused on building both the brokerage and banking businesses....We
23 are actively discussing trimming a couple of the less relevant of these companies
24 and replacing them with larger market capitalization firms which we can bank....In
25 total, I would look to us to initiate on **two** non-deal related stocks this year, keeping
the total names under coverage around the current level. In addition to two non-
deal initiations, we have mapped out the year and have planned original theme
pieces and other value-added activities for investors including non-deal related
road shows....**Banking:** We already did KPMG, for which I believe we were paid
\$12.5M. And we have been mandated as a senior co-manager on Accenture,
another large transaction. Beyond these, a likely opportunity later in the year is
Technology Partners International, an outsourcing consultant. We are well
positioned to lead this company's IPO....[An investment banker] leads the
coordinated banking effort covering the sector, and we are working closely with

1 [him] and the other coverage bankers to bank existing companies and to identify
2 quality early stage firms." (Emphasis in the original.)

3 9. In another example, an investment banker sent an e-mail, dated May 17, 2001, to
4 a group of biotechnology analysts and bankers to arrange a meeting to discuss
5 "coverage strategy." The e-mail stated: "On the heels of [a research analyst and
6 a banker] leaving, we probably need to discuss coverage strategy. Also would be
7 a good time to talk about where we might shake loose some business...M&A
8 ideas to pitch, IPOs coming in next wave etc."

9 10. In another example, a research analyst sent an e-mail, dated March 1, 2001, to
10 biotechnology analysts and the Head of U.S. Equity Research that contained the
11 following subject line: "bankers wish list for biotech research." The e-mail stated:
12 Attached is the culmination of the survey of bankers – as a reminder, I asked them
13 for 3 groups of names....1. Companies we 'owe' research to since they paid us in
14 2000 and are not covered by research today. Most of these are from analysts who
15 have left (on the H&Q side) and we haven't even had research take a formal look
16 at some of these, which is obviously the first step for deciding on what to do. 2.
17 Public companies where bankers have a good relationship and think we can get
18 banking business if research is on board. The goal here is to have research
19 evaluate the story as soon as possible, so we can either go full bore on getting the
20 business, or re-assign bankers elsewhere if research is negative. 3. Private
21 companies that are focus names—we'll commit to have research spend time with
22 these companies as much as possible before the IPO to put us in the best position
23 possible to win the books. Also, research is going to add their own names if some
24 of their favorites were not mentioned by any of the bankers."

25 11. The following e-mails reflect the IB influences in the initiation and maintenance of
research coverage as perceived by an individual research analyst.

12. In an e-mail dated November 2, 2000, a research analyst provided a team review
of an investment banker that stated the following: "I have worked with [the banker]
on the International Rectifier (IRF) account since around mid-1998...and he
lobbied me very actively to pick up coverage so that JPM could go after the
banking business, especially equities but also potentially debt, M&A, etc. My
attitude initially was that IRF is a low-grade semiconductor company that would be
hard to sell to buy-side clients, but [he] kept pushing the banking
potential....Finally, I picked up coverage in December 1998.... Then, IRF threw
sand in our eyes by giving the lead to Morgan Stanley....We picked up coverage
when they needed us most at the bottom of the semiconductor cycle and
supported the stock enormously. When the plum banking assignment came up
that would pay us back for our support, IRF handed the deal to MS, which had
zero history with the company."

13. In an e-mail dated August 8, 2000, the same research analyst stated: "Given how
thoroughly we just got screwed on IRF, [the Head of Research of RESPONDENT
JPMSI] is not interested in hearing stories about how if we initiate coverage, then
we will be considered for banking business. He wants to hear that the banking
business is locked up. We've been screwed too many times...[O]ur not covering

1 IFX [Infineon Technologies] is a direct result of being offered money-losing table
2 scraps in the IPO....I guess I'm still in the same old place. Initiating coverage of
3 IFX some time in the next six months is no problem, especially as [a research
4 analyst] is going to have to cover it eventually anyway. It doesn't make sense to
5 have a European semiconductor analyst that does not cover Infineon." (Emphasis
6 in the original.)

7
8 14. In addition, consideration of "investment banking sensitivities" was included in a
9 discussion of the Firm's "Long Term Buy" ("LTB") research rating.

10 15. An e-mail dated December 29, 2000, which was sent to all Chase H&Q research
11 analysts, including the Head of Research at Chase H&Q, described the stock
12 rating system to be used after the merger of JPM and Chase.

13 16. The e-mail's subject line stated: "Public dissemination of coverage and Re-Rating
14 your stocks—IMPORTANT****." The e-mail stated: **The guidelines for
15 determining the rating are below.... Long-Term Buy: 0-10% outperformance
16 of the relevant benchmark target within a twelve to eighteen month time
17 frame. Shorter-term catalysts to explain the 'longer-term' nature of the
18 recommendation, or in certain circumstances investment banking
19 sensitivities, are appropriate for this designation.** (Emphasis in the original.)

20 **F. The Firm Provided Certain Companies With an Informal "Warranty" of Research 21 Coverage in Conjunction With Investment Banking Transactions**

22 1. The Firm typically initiated research coverage on companies that engaged the
23 Firm in an IB transaction.

24 2. H&Q and Chase H&Q had an informal policy of providing certain companies with a
25 "warranty" of research coverage in conjunction with IB transactions.

1 3. For example, in an e-mail dated November 22, 2000, and sent by the Head of
2 eBusiness at Chase H&Q to the Head of Research at Chase H&Q and others, the
3 Head of eBusiness stated the following: "I think that it is important to guaranty [sic]
4 some level of consistent coverage for our fee paying IB clients. In terms of a
5 'warranty period,' I think that a period of 18 months would be a fair and appropriate
6 coverage period, as well as a reasonable timeframe for a company to show
7 progress and perhaps 'earn' an extension of coverage. During this transition
8 period...we could offer more of a general, maintenance-only, 'no name' research
9 coverage...[that] could be done by a 'team' of junior associates from both the IB
10 and research side of the house as part of the 'pod' approach to a sector. This
11 coverage would allow the pod to continue to maintain a relationship with the
12 company, generating additional income from the account."

13 4. The Firm verbally promoted this warranty research coverage in conjunction with
14 pitches of IB business to companies, and research coverage would be maintained
15 on certain companies subject to the warranty.

- 1 5. For example, in an e-mail dated October 20, 1999, an investment banker sent an
2 e-mail to senior executives at H&Q that contained the following subject line:
3 "Follow Up on a Pitch Please." The e-mail stated: [Head of IB:] Please call...[the]
4 Chairman of CCC Info. Services....Script: You know that [a team of investment
5 bankers] presented to the board yesterday and that we are very excited about the
6 prospect of serving as agent for a private round with financial and strategic parties
7 and as lead manager on their IPO in early 00....Our pitch is...4. Best aftermarket
8 'warranty.'"
6. Also, in an e-mail dated December 19, 2000, from an investment banker to a
member of the board of directors of Epicor Software Corporation ("Epicor"), the
banker stated: "Just a heads up that the extended warranty provided for Epicor is
running out." In an e-mail dated December 22, 2000, the board member replied:
"not a surprise. thanks for sticking to the deal."

9 **G. The Firm's Pitch Materials Contained Discussions of Research Coverage**

- 10 1. During the relevant period, companies considered research coverage to be an
important factor in selecting a firm for an underwriting transaction.
- 11 2. In certain pitch materials, the Research Department, and research analysts in
12 particular, were described to implicitly suggest that the Firm would provide
13 favorable research coverage after the IB transaction.³ The research analyst's
14 reputation and industry ranking, statistics regarding the percentage of lead- and
15 co-managed IPOs currently under coverage, and the Firm's "aftermarket support"
16 were promoted in pitch materials. In addition, the Firm utilized "case studies" of
companies under coverage that included charts comparing the dates of positive
published research to the company's stock price. The case studies showed the
stock price increases following the analyst's positive recommendation and/or
placement on the analyst's or the Firm's "Focus Lists."
- 17 3. For example, in an e-mail dated February 23, 2000, an investment banker
18 forwarded pitch materials to an employee of Participate.com to persuade the
19 company to employ the Firm as an underwriter for an upcoming IPO and private
20 offering. The pitch materials identified the research analyst who would cover the
company after the IB transaction. In pages captioned "[Research analyst's name]:
Authoritative Voice in the Marketplace," "case studies" were presented on the
analyst's past coverage of two companies: Wireless Facilities and AppNet.
- 21 4. The case studies contained charts that showed the stock price increases following
22 placement of the stocks on the analyst's and Firm's focus lists. The "Wireless
23 Facilities Case Study" stated the following: "Chase H&Q adds WFI to Focus List:
24 WFI gains 11.7% (1/27/00)." The "AppNet Case Study" stated the following:
"Chase H&Q adds AppNet to Focus List: AppNet gains 7.5% (8/2/99)...While on
[the research analyst's] Focus List, AppNet appreciates 309% (8/2/99-10/26/99)."

25 ³ "Pitch materials" are the written materials provided to the management of an issuer in conjunction with the Firm's pitch or presentation of its strengths and capabilities in conducting an upcoming IPO or other IB transaction.

- 1
2
3
5. Also presented were excerpts of positive commentary by the research analyst that accompanied the Buy ratings and/or placement on the focus lists.

4

H. Research Analysts Were Visible on Stocks to Generate Investment Banking Business

- 5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
1. Research analysts were encouraged to increase their visibility, or level of communication, on certain stocks to generate IB business.
 2. Lists of stocks were distributed to various departments at the Firm, including the Research Department.
 3. The "ECM [Equity Capital Markets] target list" contained stocks of companies from which the Firm was seeking IB business during the next eighteen (18) months.
 4. The "trading focus list" contained stocks of companies from which the Firm was seeking IB or underwriting business during the next three months.
 5. The Research Department and other departments were at times encouraged to increase the trading volume of the stocks on the lists for IB purposes.
 6. The following e-mail, dated May 11, 2001, and sent from an investment banker to individuals on the "IB Ebusiness" distribution list, explains the rationale for the two lists: "The criteria for being on the [ECM target] list is...potential equity business over the next 18 months where we would like to target the resources of the firm to win the books....Our objective is to make sure we are being as proactive as possible from an equity perspective, and focusing the equity resources of the firm on these targets to help you win the books for these transactions....The criteria for being placed on the trading focus list is an investment banking event with [sic] the NEXT THREE MONTHS....This investment banking list could be an m&a event or an equity event....In cases where the investment banking event will occur far in advance, our first approach is to work with the traders, analysts and sales traders to increase our trading activity naturally, before we start spending the firm's capital." (Emphasis in the original.)
 7. Trading rank was important to a company's choice of a firm for IB transactions, and the Firm's trading rank was often promoted in pitch materials provided to potential IB clients.
 8. For example, pitch materials provided in conjunction with the AppNet IPO contained a section entitled, "Commitment to Corporate Clients Delivers Institutional Credibility and Trading Strength." There, H&Q's Autex trading rank is identified as "#1," "#2," "#3," and "#4" in the stocks of specific companies that engaged H&Q for an IPO.
 9. Certain research analysts were encouraged to increase their visibility, or level of communication, on stocks contained in the lists.

- 1 10. For example, in an e-mail dated September 27, 2000, from an investment banker,
2 to a research analyst and others, the banker forwarded September's focus list and
3 stated: "The list is okay but we are falling way short on a few names. Vicinity we
4 are not AT [sic] the goal, we are below the goal for the past two months. This is a
5 problem. On Intertrust and Mypoints, we are not even close to our targets. Less
6 critical, but we need to do a better job. Concord EFS paid us \$5 MM last year and
7 we are the #18 trader of that stock. Also disappointing...[Y]ou [research analyst]
8 need to get more visible on these names with the salespeople so that trading
9 doesn't have that excuse to hide behind."

I. Payments for Research

- 7 1. During the relevant period, H&Q and Chase H&Q made seven payments totaling
8 \$1,312,500 for research issued in conjunction with five underwriting transactions in
9 which the Firm was a lead- or co-manager.
- 10 2. H&Q and Chase H&Q made these payments for research without disclosing or
11 ensuring their disclosure in offering documents or elsewhere.

J. The Firm Failed to Adequately Supervise Its Research and Investment Banking Departments

- 12 1. While the role of research analysts was to produce objective research, the Firm
13 also encouraged them to participate in IB activities.
- 14 2. In addition, the Research and IB Departments had a formal connection within the
15 Firm's organizational structure. From February to December 2000 at
16 RESPONDENT JPMSI, the Head of Research had a dual reporting line to both the
17 Head of Equities and the Head of Investment Banking.
- 18 3. Also, in 2000 at Chase H&Q, research analysts were organized and placed into
19 "Analyst Sub-pods" for purposes of managing and monitoring their IB activities.
20 Research analysts reported to "Sub-pod Managers," who were investment bankers
21 and were responsible for the day-to-day coordination of the research analysts' IB
22 activities.
- 23 4. The Analyst Sub-pod system for Chase H&Q "Internet Research and Banking" is
24 explained in a May 2000 Chase H&Q interoffice memorandum which contained a
25 "coordination chart." In the chart, the Analyst Sub-pods had a direct reporting line
to the Sub-pod Managers. The memorandum stated the following: "The 'Analyst
Sub-pod' is the organizational engine for all that we do." Sub-pod Managers, who
were investment bankers, were responsible for the "pipeline management
and...the day-to-day coordination of the particular analyst as it relates to
investment banking activity....The Sub-pod Manager is not responsible for
executing all of that particular analyst's transactions, but is responsible for
ensuring that appropriate resources are allocated. As such, the Sub-pod Manager
should expect to spend a majority of his time banking the Sub-pod Analyst with the
balance of his time spent banking other analysts as the demands of the business
require it." (Emphasis in the original.)

1 5. The Analyst Sub-pod system was created to provide "enhanced coordination
2 between Banking and Research."

3 6. As a result of the foregoing, research analysts were subject to IB influences and
4 conflicts of interest between supporting the Firm's IB business and publishing
5 objective research. The Firm had knowledge of these IB influences and conflicts
6 of interest yet failed to manage them adequately to protect the objectivity of
7 published research.

8 7. The Firm failed to establish and maintain adequate policies, systems, and
9 procedures reasonably designed to ensure the objectivity of its published
10 research. Although the Firm had some policies governing research analysts'
11 activities during the relevant period, these policies were inadequate and did not
12 address the IB influences and conflicts of interest that existed.

13 CONCLUSIONS OF LAW

14 1. The Division has jurisdiction over this matter pursuant to The Alaska Securities Act.

15 2. The Division finds that Respondent JPMSI failed to establish and enforce written
16 supervisory procedures reasonably designed to ensure that analysts were not unduly
17 influenced by investment banking concerns in violation of AS 45.55.060(a)(7) and (b)(1).

18 3. The Division finds that Respondent JPMSI engaged in acts and practices that
19 created or maintained inappropriate influence by the IB Department over research analysts,
20 therefore imposing conflicts of interest on its research analysts, and failing to manage these
21 conflicts in an adequate or appropriate manner, constituted violations of AS 45.55.060(a)(7)
22 and (b)(1).

23 4. The Division finds that Respondent JPMSI made payments for research to other
24 broker-dealers not involved in an underwriting transaction when the Firm knew that these
25 payments were made, at least in part, for research coverage, and by failing to disclose or
cause to be disclosed in offering documents or elsewhere the fact of such payments
constituted a violation of AS 45.55.060(a)(7) and (b)(1).

5. The Division finds the following relief appropriate and in the public interest.

ORDER

On the basis of the Findings of Fact, Conclusions of Law, and JPMSI's consent to the
entry of this Order, for the sole purpose of settling this matter, prior to a hearing and without
admitting the Findings of Facts or Conclusions of Law

IT IS HEREBY ORDERED:

1. This Order concludes the investigation by the Division and any other action that the
Division could commence under applicable Alaska law on behalf of Alaska as it relates to J.
P. Morgan Securities Inc., relating to certain **research** practices at J. P. Morgan Securities
Inc.

1
2 2. J. P. Morgan Securities Inc. will CEASE AND DESIST from violating AS
3 45.55.060(a)(7) and (b)(1) in connection with research practices referenced in this Order
4 and will comply with AS 45.55.060(a)(7) and (b)(1) in connection with research practices
5 referenced in this Order and will comply with the undertakings of Addendum A,
6 incorporated herein by reference.

7
8 3. IT IS FURTHER ORDERED, ADJUDGED AND DECREED that:

9
10 As a result of the Findings of Fact and Conclusions of Law contained in this Order, J.
11 P. Morgan Securities Inc shall pay a total amount of \$80,000,000.00. This total amount
12 shall be paid as specified in the SEC Final Judgment as follows:

13
14 \$25,000,000 to the states (50 states, plus the District of Columbia and Puerto Rico).
15 Upon execution of this Order, J. P. Morgan Securities Inc. shall pay the sum of
16 \$250,000.00 of this amount to the State of Alaska as a civil monetary penalty pursuant to
17 the agreement of the parties, to be deposited in the Alaska general fund. The total amount
18 to be paid by JPMSI to state securities regulators pursuant to the state settlement offer may
19 be reduced due to the decision of any state securities regulator not to accept the state
20 settlement offer. In the event another state securities regulator determines not to accept
21 JPMSI's state settlement offer, the total amount of the Alaska payment shall not be
22 affected, and shall remain at \$250,000.00;

23
24 \$25,000,000 as disgorgement of commissions, fees and other monies as specified in
25 the SEC Final Judgment;

\$25,000,000, to be used for the procurement of independent research, as described
in the SEC Final Judgment;

\$5,000,000, to be used for investor education, as described in Addendum A,
incorporated by reference herein.

17
18 J. P. Morgan Securities Inc. agrees that it shall not seek or accept, directly or
19 indirectly, reimbursement or indemnification, including, but not limited to payment made
20 pursuant to any insurance policy, with regard to all penalty amounts that J. P. Morgan
21 Securities Inc. shall pay pursuant to this Order or Section II of the SEC Final Judgment,
22 regardless of whether such penalty amounts or any part thereof are added to the
23 Distribution Fund Account referred to in the SEC Final Judgment or otherwise used for the
24 benefit of investors. J. P. Morgan Securities Inc. further agrees that it shall not claim,
25 assert, or apply for a tax deduction or tax credit with regard to any state, federal or local tax
for any penalty amounts that J. P. Morgan Securities Inc. shall pay pursuant to this Order or
Section II of the SEC Final Judgment, regardless of whether such penalty amounts or any
part thereof are added to the Distribution Fund Account referred to in the SEC Final
Judgment or otherwise used for the benefit of investors. J. P. Morgan Securities Inc.
understands and acknowledges that these provisions are not intended to imply that Alaska
would agree that any other amounts J. P. Morgan Securities Inc. shall pay pursuant to the
SEC Final Judgment may be reimbursed or indemnified (whether pursuant to an insurance
policy or otherwise) under applicable law or may be the basis for any tax deduction or tax
credit with regard to any state, federal or local tax.

1
2 4. J. P. Morgan Securities Inc. shall comply with the undertakings of Addendum A,
incorporated herein by reference.

3 5. If payment is not made by J. P. Morgan Securities Inc. or if J. P. Morgan Securities
4 Inc. defaults in any of its obligations set forth in this Order, the Division may vacate this
5 Order, at its sole discretion, upon 10 days written notice to J. P. Morgan Securities Inc. and
without opportunity for administrative hearing.

6 6. This Order is not intended by the administrator to subject any Covered Person to
7 any disqualifications under the laws of any state, the District of Columbia or Puerto Rico
8 (collectively, "State"), including, without limitation, any disqualifications from relying upon
9 the State registration exemptions or State safe harbor provisions. "Covered Person"
means J. P. Morgan Securities Inc., or any of its officers, directors, affiliates, current or
former employees, or other persons that would otherwise be disqualified as a result of the
Orders (as defined below).

10 7. The SEC Final Judgment, the NYSE Stipulation and Consent, the NASD Letter of
11 Acceptance, Waiver and Consent, this Order and the order of any other State in related
12 proceedings against J. P. Morgan Securities Inc. (collectively, the "Orders") shall not
13 disqualify any Covered Person from any business that they otherwise are qualified,
licensed or permitted to perform under applicable law of Alaska and any disqualifications
from relying upon this state's registration exemptions or safe harbor provisions that arise
from the Orders are hereby waived.

14 8. For any person or entity not a party to this Order, this Order does not limit or create
15 any private rights or remedies against J. P. Morgan Securities Inc. including, without
16 limitation, the use of any e-mails or other documents of J. P. Morgan Securities Inc. or of
others regarding research practices, or limit or create liability of J. P. Morgan Securities Inc.
or limit or create defenses of J. P. Morgan Securities Inc. to any claims.

17 9. Nothing herein shall preclude Alaska, its departments, agencies, boards, commissions,
18 authorities, political subdivisions and corporations, other than the division of banking,
19 securities, and corporations and only to the extent set forth in paragraph 1 above (collectively,
20 "State Entities") and the officers, agents or employees of State Entities from asserting any
claims, causes of action, or applications for compensatory, nominal and/or punitive damages,
or administrative, civil, criminal, or injunctive relief, against J. P. Morgan Securities Inc. in
connection with certain research practices at J. P. Morgan Securities Inc.

21 BY ORDER OF THE ADMINISTRATOR OF SECURITIES

22 Dated this 11 day of September, 2003.

23
24
25 /s/ Mark R. Davis
Mark R. Davis
Administrator of Securities